anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: Among non-small cell lung cancers (NSCLC), 5 years is a benchmark in cancer control and treatment, but a certain percentage of cases recur after 5 years. The long-term post-recurrence outcomes remain controversial. To examine the accurate prognostic factors associated with survival and cancer recurrence among 5-year survivors, a landmark analysis that considered competing risks was performed.
METHODS: Complete resection of NSCLC was performed in 2482 patients between January 2003 and December 2015. A total of 1431 patients were 5-year survivors without recurrence. A landmark time analysis was applied to the overall survival (OS) and recurrence-free survival (RFS) from 5 years after surgery, and the findings were calculated using the Kaplan-Meier method. The cumulative incidence of cause-specific death and recurrence was estimated using the cumulative incidence function, while carefully considering the competing risks.
RESULTS: Postoperative recurrence was detected in 732 patients, of whom 68 (9.3%) had recurrence after 5 years. The median follow-up period was 8.2 years. In the competing risk analysis, the independent poor prognostic factors associated with cause-specific death were age ≥ 75 years, lymph node metastasis and pleural invasion.
CONCLUSIONS: Patients requiring a follow-up for > 5 years were aged ≥ 75 years and had either lymph node metastasis or pleural invasion.
Warts, hypogammaglobulinaemia, infections and myelokathexis syndrome (WHIMS) is a rare combined primary immunodeficiency caused by the gain of function of the CXCR4 chemokine receptor. We present the prevalence of cancer in WHIMS patients based on data from the French Severe Chronic Neutropenia Registry and an exhaustive literature review. The median follow-up of the 14 WHIMS 'patients was 28.5 years. A central review and viral evaluation of pathological samples were organized, and we conducted a thorough literature review to identify all reports of WHIMS cases. Six French patients were diagnosed with cancer at a median age of 37.6 years. The 40-year risk of malignancy was 39% (95% confidence interval [CI]: 6%-74%). We observed two human papillomavirus (HPV)-induced vulvar carcinomas, three lymphomas (two Epstein-Barr virus [EBV]-related) and one basal cell carcinoma. Among the 155 WHIMS cases from the literature, 22 cancers were reported in 16 patients, with an overall cancer 40-year risk of 23% (95% CI: 13%-39%). Malignancies included EBV-associated lymphoproliferative disorders and HPV-positive genital and anal cancers as in the French cohort. Worldwide, nine cases of malignancy were associated with HPV and four with EBV. Immunocompromised WHIMS patients appear to be particularly susceptible to developing early malignancy, mainly HPV-induced carcinomas, followed by EBV-related lymphomas.
Six QTLs of resistance to sugarcane orange rust were identified in modern interspecific hybrids by GWAS. For five of them, the resistance alleles originated from S. spontaneum. Altogether, they efficiently predict disease resistance. Sugarcane orange rust (SOR) is a threatening emerging disease in many sugarcane industries worldwide. Improving the genetic resistance of commercial cultivars remains the most promising solution to control this disease. In this study, an association panel of 568 modern interspecific sugarcane hybrids (Saccharum officinarum x S. spontaneum) from Réunion's breeding program was evaluated for its resistance to SOR under natural conditions of infection. Two genome-wide association studies (GWAS) were conducted between disease reactions and 183,842 single nucleotide polymorphism (SNP) markers obtained by targeted genotyping-by-sequencing. Five resistance quantitative trait loci (QTLs), named Oru1, Oru2, Oru3, Oru4 and Oru5, were identified using a single-locus GWAS (SL-GWAS). These five QTLs all originated from the species S. spontaneum. A multi-locus GWAS (ML-GWAS) uncovered an additional but less significant resistance QTL named Oru6, which originated from S. officinarum. All six QTLs had a moderate to major phenotypic effect on disease resistance. Prediction accuracy estimated with linear regression models based on each of the five QTLs identified by SL-GWAS was between 0.16-0.41. Altogether, these five QTLs provided a relatively high prediction accuracy of 0.60. In comparison, accuracies obtained with six genome-wide prediction models (i.e., GBLUP, Bayes-A, Bayes-B, Bayes-C, Bayesian Lasso and RKHS) reached only 0.65. The good prediction accuracy of disease resistance provided by the QTLs and the predominant S. spontaneum origin of their resistance alleles pave the way for effective marker-assisted breeding strategies.
Patients receive oral imatinib mesylate 400mg once daily for 3-12 months in the absence of disease progression or unacceptable toxicity. Within 1 week after completion of preoperative imatinib mesylate, patients with responding or stable disease undergo surgical resection. After complete resection, patients receive oral imatinib mesylate 400mg once daily for 36 months in the absence of disease progression or unacceptable toxicity, and are followed for 5 years.
Clinical assessments at baseline, 7 and 10 weeks. fMRI assessments at baseline and 10 weeks.
INTRODUCTION: The NHS has made it mandatory for General Practices in England to proactively identify and manage older people with moderate and severe frailty since the GMS contract of 2017/2018. In Luton, stakeholders developed the Luton Framework of Frailty (LFF) to implement this national policy. The aim of this study was to explore the factors that affect the implementation of this national policy at a local level.
METHODS: In-depth interviews were conducted with 18 commissioners and service providers, all of whom were involved in providing services for older people with different frailty levels (OPDFL). Purposive and snowball sampling methods were used, with thematic analysis used for data analysis.
RESULTS: Two main themes with several sub-themes were found. The first theme was the tension within existing national policy initiatives to provide integrated care services for OPDFL, which illuminated their strengths and limitations. Participants felt that new initiatives, such as the development of Primary Care Networks and Enhanced Health in Care Homes, have improved primary care coordination. However, the traditional reactive approach for managing older people who are frail was thought to be counterproductive, when an approach that focused on prevention and early intervention would have been better. The second theme concerned the contextual factors that affect implementation of integrated care. These included having key leaders at a local level, the requirement for more funding, as well as the need for good working relationships among service providers. However, the lack of awareness about the care pathways among GPs was thought to be a reason for the variation in the implementation of the LFF. The COVID-19 pandemic was perceived as a challenge for the implementation of the LFF. Finally, polices were thought to succeed only if more resources are provided, while the term frailty should be used with caution due to the negative connotations of OPDFL towards this term.
CONCLUSION: The implementation of an integrated care programme for OPDFL can be affected by several factors. Having proactive national policies that facilitate coordination and, having key leaders locally, the need for more funding, and good working relationships, are some of the contextual factors that could facilitate a successful implementation. In contrast, the lack of awareness of the care pathways that have been introduced locally, insufficient resources to deliver the programmes efficiently and a lack of careful consideration of how the term frailty is used could hinder this being put into practice.
AIM2ACT is the experimental arm for the trial. AIM2ACT is a dyadic mHealth intervention designed to sustain caregiver involvement and monitoring as well as guide dyads through collaborative asthma management.
Standard oral care recommendations. Participants in all groups will receive the same recommendations. Questionnaires - Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
PURPOSE: To evaluate and compare the clinical results of different single-use flexible ureteroscopes (su-fURS) used in retrograde intrarenal surgery (RIRS).
MATERIALS AND METHODS: RIRS cases performed identically by an experienced surgeon between 2022 and 2023 in a single center were retrospectively analyzed. These surgeries were performed with three su-fURS (Redpine RP-U-C12, Hugemed HU30, and Pusen Uscope 3022 A). In the study, the age, gender, body mass index, and Charlson comorbidity index of the patients were compared, along with their clinical details, such as the stone size, volume, density, location, and history of hydronephrosis or a double J stent or SWL. Operation time, stone-free rates (SFR), perioperative and postoperative complications, and hospitalization times were also compared.
RESULTS: The study included 208 patients. Pusen had 63 cases, Hugemed had 62, and Redpine had 83. The comparison of the patient's demographic and clinical properties with stone-related variables was similar between the groups. The SFR was similar between the groups (p = 0.056). Perioperative, postoperative, and total complication rates and the need for a second intervention showed no significant differences among the three groups (p = 0.324, 0.088, 0.061, and 0.052, respectively).
CONCLUSION: In the first study comparing the clinical results of cases in which different su-fURS were used, no difference was observed in surgical outcomes and complications, even though the technical features of these devices were different. Urologists should select su-fURS based on clinical requirements, financial constraints, and personal experiences.
The invention relates to a cold remedy containing dexibuprofen. The invention is characterized in that the invention include the following drugs by weight: 1part of dexibuprofen, 0.01-0.2 part of antiallergic drugs, 0-0.5 part of nasal mucosa hyperemia alleviating drug, 0-1 part of antiviral drug, 0-100 parts of alky auxiliary solvent, 0-100 parts of loading agent, 0-0.5 part of correctant, 0-2 parts of lubricant, 0-500 parts of hydrosolvent and 0-12 parts of adhesive. The invention can be prepared into any dosage form acceptable in pharmaceutics. The invention overcomes the shortcomings of great side effect and large dosage of the existing medicines like ibuprofen, acetaminophen, phenacetin, aminophenazone and aspirin. The invention can eliminate inflammation, relieve pain and fever. The indications of the invention are fever, headache, rhinorrhea and rhinitis. Generally, these symptoms can be healed within 2-4 days.
Thyroid carcinoma incidence has been on the rise in recent years. Papillary thyroid carcinoma is the most prevalent type of differentiated thyroid carcinoma, accounting for 85% to 90% of malignant thyroid tumors. Despite its indolent nature, cervical lymph node metastasis is frequently observed at an early stage. Papillary thyroid carcinoma patients with cervical lymph node metastasis face an elevated risk of recurrence, distant metastasis, and mortality. Thus, non-invasive preoperative prediction of cervical lymph node metastasis is particularly vital for guiding treatment plans and prognostic. this study has developed a multimodal model integrating preoperative US images with cytological images of papillary thyroid carcinoma patients. The aim is to enhance the predictive accuracy for cervical lymph node metastasis, reduce unnecessary lymph node dissections, and provide real-time, precise guidance for determining the extent of surgical resection and prognostic assessment. This approach aims to optimize patient treatment strategies and enhance therapeutic outcomes.
FIELD: medicine, phytotherapy. SUBSTANCE: an agent has burdock leaves extract at the following ratio of components, %: burdock leaves extract 5; 40% ethyl alcohol 95. Dried burdock leaves are milled (to the size 3 mm), extracted with 40% ethyl alcohol at the ratio raw : extractant = 1:20, infused at the room temperature for 7-10 days at the periodic stirring. Then extract is filtered, the raw is squeezed out good, the volume of obtained extract is measured and residue is washed out with extractant again at amount that was lost in the first extraction and both parts are combined. EFFECT: broadened assortment of antiulcer agents, simplified method of preparing. 2 cl, 7 tbl, 1 ex
Obesity is an important health concern that poses many public health challenges. Evidence-based treatment modalities, capable of cost-effectively reaching large patient groups are needed. In this paper, we present the design and methods of the updated national, 12-month, digital weight management program, the Healthy Weight Coaching (HWC). The major updates, as compared to the previous version, are related to the theoretical background of the obesity management and updated BMI cut-offs. The HWC is available, based on physicians' referrals, to adult Finnish citizens with BMI ≥30 kg/m2 or ≥27 kg/m2 with a comorbidity, who have a health-based need to lose weight. Rooted in the principles of behavioural therapy, the HWC focuses on teaching coping skills, guides to healthy self-reflection, and supports concrete lifestyle changes as part of healthy weight loss. The automated weekly training sessions, supplemented by 3-8 exercises, form the basis of the program. These sessions address topics such as diet, physical activity, stress management, and rest and recovery. Additionally, a personal coach is allocated to each patient to provide tailored support. At baseline, patients record their weight, height, and waist circumference, online, and complete questionnaires on lifestyle, diet, physical activity, sleep, psychological factors, and health. Thereafter weight recording is conducted at least every 4 weeks, while the questionnaires and measuring the weight circumference are repeated at 3, 6, 9, and 12 months. In addition, patients can make use of diaries and peer group chats for additional support. Data collected from the consenting patients will be used for research purposes with the weight change from baseline to 12 months as the main outcome in the real-life observational study. The study will provide invaluable insights into the application of digital modalities in the treatment of obesity.
Disclosed are a compound having an antibacterial activity and a derivative thereof, more preferably an antibacterial nucleoside compound that can inhibit the activity of MraY to exert an antibacterial activity and a derivative of the nucleoside compound, particularly a novel derivative of Muraymycin that is an MraY inhibitor. Specifically disclosed is a novel derivative of Muraymycin or a pharmaceutically acceptable salt thereof. The compound has good intracellular penetration properties and a potent antibacterial activity. The compound also has resistance against enzymes such as an esterase occurring in blood. A preferred embodiment of the compound has an inhibitory activity on MraY. The preferred embodiment of the compound is effective against resistant bacteria such as VRE and MRSA.
Two-phase gel compositions are provided. The two-phase gel compositions are obtained by mixing a gelled ester composition comprising a mixture of an ester compound and a polymer compound selected from the group consisting of triblock copolymers, star polymers, radial polymers, multi-block copolymers, and a combination thereof and a hydrophobic, non polar solvent. The gelled ester composition has a viscosity η 1  and the solvent has a viscosity η 2 . The two-phase gel composition is substantially free of phosphate compounds and has a viscosity η which is greater than or equal to η 1  and which is greater than or equal to η 2 . The two-phase gel compositions are also obtained by mixing a gelled ether composition, a gelled alcohol composition, a gelled naturally-occurring fat and oil composition or a combination thereof with a hydrophobic, non polar solvent. The two-phase gel compositions may be used to suspend various solids, liquids and/or gases.
The phase II portion of the study will use the maximum tolerated dose of dasatinib determined in the phase I portion. Osimertinib (AZD9291) will be given at the same 80mg dose as the phase I portion. There is no limit to the number of cycles a patient can receive.
OBJECTIVES: Bariatric surgery improves metabolic health, but the underlying mechanisms are not fully understood. We analyzed the effects of two types of bariatric surgery, sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB), on the plasma metabolome and lipidome.
METHODS: We characterized the plasma metabolome (1268 metabolites) and lipidome (953 lipids) pre-operatively and at 3 and 12 months post-operatively in 104 obese adults who were previously recruited to a prospective cohort of bariatric surgery. The metabolomic and lipidomic responses to bariatric surgery over time were analyzed using multivariable linear mixed-effects models.
RESULTS: There were significant changes in multiple metabolites and lipids, including rapid early changes in amino acid and peptide metabolites, including decreases in branched-chain amino acids (BCAAs), aromatic AAs, alanine and aspartate, and increases in glycine, serine, arginine and citrulline. There were also significant decreases in many triglyceride species, with increases in phosphatidylcholines and phosphatidylethanolamines. There were significant changes in metabolites related to energy metabolism that were apparent only after 12 months. We observed differences by bariatric surgery type in the changes in a small number of primary and secondary bile acids, including glycohyocholate and glyco-beta-muricholate.
CONCLUSIONS: Our findings highlight the comprehensive changes in metabolites and lipids that occur over the 12 months following bariatric surgery. While both SG and RYGB caused profound changes in the metabolome and lipidome, RYGB was characterized by greater increases in bile acids following surgery.
The invention relates to systems for structuring clinical trials protocols into machine interpretable form. A hybrid human and natural language processing system is used to generate a structured computer parseable representation of a clinical trial protocol and its eligibility criteria. Furthermore, a web-based search engine to allow patients to find relevant clinical trials is developed. It works by asking a series of questions, which are generated dynamically such that previous answers will decide which question is generated next. Using a probabilistic model of trial suitability, questions are prioritized so as to minimize the total question burden. Furthermore, data collected across multiple trials is used to optimize the model and to optimize the design of future clinical trials.
Subjects will receive placebo in P-1, GSK1325756H 50 mg in P-2 and GSK1325756H 100 mg in P-3 after a high fat meal. There will be a washout period of at least 7 days between each treatment period.
The study is a prospective, observational cohort study. Using risk factors for HFpEF, the Danish National Health Registries will be used to identify up to 5000 citizens with at least one risk factor for HFpEF relying on International Classification of Diseases, 10th revision (ICD-10), medication, and biochemistry. The investigators will only recruit patients from the Capital Region of Denmark. Participants will be recruited by sending recruitment letters to a secure electronic mailbox (eBoks) linked to the patients' social security numbers.

The purpose of this study is to evaluate the identification and screening procedures for HFpEF outlined in this protocol. Additionally, the investigators aim to gauge the willingness of identified Danish adults with risk factors for HFpEF to participate in the study and to identify and address any barriers to their involvement. Overall, the investigators expect the results of this study can be used to guide future initiatives aimed at improving the identification and enrollment of patients with HFpEF, particularly among vulnerable populations.
NEW MATERIAL:A dibenzo[a,d]cycloheptene derivative shown by the formula I (R1 is H, halogen, lower alkyl; R2 and R3 are H or lower alkyl; Z is group shown by the formula II or III). EXAMPLE:10,11-Dihydro-11-oxo-5H-dibenzo[a,d]cycloheptene-2-acetic acid. USE:A strong anti-inflammatory agent having extremely samll gastor-intestinal disorder. PROCESS:For example, a novel compound shown by the formula IV (X is OH or halogen; one of Y is -CH2COX and the other is H) is subjected to ring closure, optionally hydrolyzed, and then optionally converted into an ester and/or enolether to give a compound shown by the formula I. The novel compound shown by the formula I. The novel compound shown by the formula IV is obtained by reducing the carbonyl group of a compound shown by the formula V (one of Y is -CH2COOH and the other is H) into methylene group, followed by converting optionally the reaction product into a halogenated carboxylic acid.
The invention discloses a method for determining active ingredients of a rhizoma smilacis glabrae medicinal material, relating to the filed of medicament analysis. In the invention, a fingerprint taking an astilbin chromatographic peak as an internal reference peak is established. The method comprises the following steps of: (a) preparing a test article solution; (b) taking astilbin as a reference substance and taking 0.10mg/mL astilbin solution prepared from methanol as a reference substance solution; (c) chromatographic conditions: taking a chromatographic column made of octadecylsilane chemically bonded silica as filler; adopting gradient elution, detecting the wavelength of 325+/-2 nm and the column temperature of 30+/-5DEG C; calculating the theoretical column plate number not less than 3,000 according to astilbin peak; and (d) determining. The fingerprint established by rhizoma smilacis glabrae ethanol-soluble extractives contains active ingredients with main activity of rhizoma smilacis glabrae. The fingerprint is used for judging the quality of rhizoma smilacis glabrae and the one sidedness for judging the quality of rhizoma smilacis glabrae by determining one or two chemical components can be avoided. The method has the advantages of simpleness, convenience, stability, high precision, favorable reproduction, easy grasp and capability of rapidly and accurately identifying the authenticity and merits of products.